MedTrace Logo

Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer

NCT04922853 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 554

Last updated 2025-07-11

No results posted yet for this study

Summary

To compare the pathological effect between 2 cycles and 4 cycles of Capox regimen as neoadjuvant chemotherapy for low/ intermediate risk stage II/III rectal cancer.

Conditions

Interventions

DRUG

Capox chemotherapy

oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals

Sponsors & Collaborators

  • The Third People's Hospital of Chengdu

    collaborator OTHER

  • Chengdu Fifth People's Hospital

    collaborator OTHER

  • Peking Union Medical College

    collaborator OTHER

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER

  • Yunnan Cancer Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • The Affiliated Hospital Of Guizhou Medical University

    collaborator OTHER

  • Sichuan Provincial People's Hospital

    collaborator OTHER

  • Nanchong Central Hospital

    collaborator OTHER_GOV

  • Dazhou Central Hospital

    collaborator OTHER

  • Leshan People's Hospital

    collaborator UNKNOWN

  • GeneCast Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • West China Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-26
Primary Completion
2024-10-01
Completion
2027-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04922853 on ClinicalTrials.gov